U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT06888232) titled 'Safety and Efficacy of Immunomodulator Drug Thalidomide in Multi-transfused Thalassemia Patients' on March 15.
Brief Summary: This study aimed to determine the safety and efficacy of thalidomide in multi-transfused thalassemic children.
Study Start Date: Aug. 01, 2023
Study Type: INTERVENTIONAL
Condition:
Thalassemia
Intervention:
DRUG: Thalidomide
Thalidomide was administered at a dose of 1.5 mg/kg/day, and all patients continued standard iron chelation therapy and other supportive treatments as per institutional protocols.
Recruitment Status: COMPLETED
Sponsor: Muhammad Aamir Latif
Information provided by (Responsible P...